Ranibizumab for macular edema due to retinal vein occlusions: Implication of VEGF as a critical stimulator
DOI 10.1038/mt.2008.10, PII MT200810
P.A. Campochiaro, G. Hafiz, and S.M. Shah Ranibizumab for macular edema due to retinal vein occlusions; implication of VEGF as a critical stimulator Mol Ther 16 4 2008 791 799 (Pubitemid 351426182)
Ranibizumab for macular edema following branch retinal vein occlusion: 6-month primary endpoint results of a phase III study
P.A. Campochiaro, J.S. Heier, and L. Feiner Ranibizumab for macular edema following branch retinal vein occlusion: 6-month primary endpoint results of a phase III study Ophthalmology 117 6 2010 1102 1112
(2010)Ophthalmology, vol.117, Issue.6, pp. 1102-1112
Efficacy and safety of ranibizumab in the treatment of macular edema secondary to central retinal vein occlusion: 6-month results of the phase III CRUISE study
D.M. Brown, P.A. Campochiaro, and R.P. Singh Efficacy and safety of ranibizumab in the treatment of macular edema secondary to central retinal vein occlusion: 6-month results of the phase III CRUISE study Ophthalmology 117 6 2010 1124 1133
(2010)Ophthalmology, vol.117, Issue.6, pp. 1124-1133
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study
D.M. Brown, P.A. Campochiaro, and R.B. Bhisitkul Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study Ophthalmology 118 8 2011 1594 1602
(2011)Ophthalmology, vol.118, Issue.8, pp. 1594-1602
Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: 12-month outcomes of a phase III study
P.A. Campochiaro, D.M. Brown, and C.C. Awh Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: 12-month outcomes of a phase III study Ophthalmology 118 10 2011 2041 2049
(2011)Ophthalmology, vol.118, Issue.10, pp. 2041-2049
Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusion: Two-year outcomes
P.A. Campochiaro, G. Hafiz, and R. Channa Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusion: two-year outcomes Ophthalmology 117 12 2010 2387 2394
(2010)Ophthalmology, vol.117, Issue.12, pp. 2387-2394
Ranibizumab for macular edema due to retinal vein occlusions: Long term follow-up in the HORIZON trial
J.S. Heier, P.A. Campochiaro, and L. Yau Ranibizumab for macular edema due to retinal vein occlusions: long term follow-up in the HORIZON trial Ophthalmology 119 4 2012 802 809
Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1
Early Treatment Diabetic Retinopathy Study Research Group T.
The Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1 Arch Ophthalmol 103 12 1985 1796 1806
Standard care vs corticosteroid for retinal vein occlusion (SCORE) study for evaluation of stereoscopic color fundus photographs and fluorescein angiograms: SCORE study report 9
B.A. Blodi, A. Domalpally, and I.U. Scott Standard care vs corticosteroid for retinal vein occlusion (SCORE) study for evaluation of stereoscopic color fundus photographs and fluorescein angiograms: SCORE study report 9 Arch Ophthalmol 128 9 2010 1140 1145